AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03093272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
Study NCT03093272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
Study NCT03752398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®23104
Description: Monoclonal bispecific antibody
Study NCT04372394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
Study NCT01387334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training Program With Rubber Bands
Description: Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
Study NCT03885817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training and nutritional guide
Description: 30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
Study NCT03885817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard follow-up care
Description: standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
Study NCT03885817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up care
Description: standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
Study NCT03851549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New BGMS (US)
Description: New blood glucose monitoring system / In vitro diagnostic device (IVDD)
Study NCT00487305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
Description: Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
Study NCT04645550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
Study NCT04645550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
Study NCT04645550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
Study NCT04645550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study NCT04645550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study NCT00532220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate IV
Description: Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
Study NCT00532220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
Study NCT01052233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Description: Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
Study NCT01052233 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopy (diagnostic)
Description: Diagnostic arthroscopy of the knee
Study NCT00473811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low GI
Description: low-GI education
Study NCT00473811 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: ADA dietary education
Study NCT02678091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam with Doppler
Description: Ultrasound exam of the orbit
Study NCT02952768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ultrasound training
Description: Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
Study NCT04563559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
Study NCT04563559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
Study NCT02230358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia
Study NCT02230358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: General anesthesia
Study NCT02230358 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler ultrasonography
Description: 6x for 4 hours
Study NCT02230358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood gas analysis
Description: 6 x 3 ml blood withdrawal (18 ml) within 4 hours
Study NCT02230358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: invasive arterial blood pressure measurement
Description: before operation, 8 hours, as done in clinical routine
Study NCT02230358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: arterial blood gas measurement
Description: perioperative, 4-6 times within 8 hours, as done in clinical routine
Study NCT02010216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg by intravenous infusion every 4 weeks
Study NCT01769417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01769417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4893
Description: Human immunoglobulin G1 kappa monoclonal antibody
Study NCT02438995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial Cetxuimab (Erbitux)
Description: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
Study NCT02364167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
Study NCT02364167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
Study NCT02364167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
Study NCT02364167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan
Study NCT02364167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan
Study NCT02771249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentene (RPT)
Description: RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
Study NCT02771249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (DRV/c)
Description: DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
Study NCT02771249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
Study NCT02771249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Study NCT00532961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% and tobramycin 0.3%
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
Study NCT00532961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% and tobramycin 0.3%
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
Study NCT02170805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS capsule formulation A
Description: BIBR 1048 MS, formulation A 50 mg
Study NCT02170805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS capsule formulation B
Description: BIBR 1048 MS, formulation B 50 mg
Study NCT02170805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS powder plus solution
Description: BIBR 1048 MS, powder plus solution 50 mg
Study NCT02230358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurological Control
Description: perioperative, 2-3 days, as done in clinical routine
Study NCT02230358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS monitoring
Description: perioperative, for 5 hours, as done in clinical routine
Study NCT02230358 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: oxygen supply (not invasive 'Vigileo')
Description: perioperative for 5 hours, as done in clinical routine
Study NCT02171663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT04421391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QuadraMune(TM)
Description: QuadraMune(TM) is a commercially available nutritional supplement
Study NCT00595205 — intervention group
Intervention type: OTHER
Intervention: Hospital log review.
Description: Reviewing of the hospital log to monitor for the occurrence of intussusception.
Study NCT03450096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LPB
Description: A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
Study NCT03197246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVECG
Description: Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
Study NCT03197246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
Study NCT03197246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
Study NCT01282944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
Study NCT01282944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network
Description: Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
Study NCT03752398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yervoy® (ipilimumab)
Description: Monoclonal antibody
Study NCT02675959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
Study NCT01726127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli and Brussels Sprouts
Study NCT01726127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cruciferous Complete
Study NCT01726127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02997657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: Exercises designed to boost moods, positive behaviors, and positive cognitions.
Study NCT02997657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation counseling
Description: Counseling designed to provide support and problem solving for smoking cessation
Study NCT02997657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation counseling
Description: Counseling designed to provide support and problem solving for smoking cessation
Study NCT02453633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional SMS text
Description: SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS.
Study NCT02453633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SMS text
Description: SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS.
Study NCT02716350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS
Description: comparison versus placebo
Study NCT02716350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: placebo
Study NCT00256776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (Bortezomib)
Study NCT00256776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Study NCT00256776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT00256776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT00256776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02244749 — intervention group
Intervention type: OTHER
Intervention: skin specimen
Description: skin specimen
Study NCT02947620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Atorvastatin 1500mg/40mg, QD
Study NCT02947620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1500mg, QD
Study NCT02947620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 40mg, QD
Study NCT04211519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sampling
Description: sampling from endodontically infected primary and permanent teeth by using paper point method
Study NCT03679273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Abound
Description: Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
Study NCT00831025 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous monthly administration
Study NCT04517929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy
Description: 9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
Study NCT00672646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 95mg, oral solution, single dose
Study NCT00672646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg, capsule, single dose
Study NCT00672646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AZD1386 Placebo oral solution
Study NCT01552993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol mixture 20 mg/kg + pacifier and glucose
Study NCT01552993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: pacifier and sucrose
Study NCT01981980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
Study NCT01981980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
Study NCT00191139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
Study NCT00191139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
Study NCT00191139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
Study NCT01174524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gestoden 60 mcg
Description: gestoden 60 mcg, once a day, administered in 24/4 regimen.
Study NCT00191139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
Study NCT01174524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinylestradiol 15 mcg
Description: ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
Study NCT00191139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
Study NCT00991718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 oral capsules (non-labeled)
Description: 150 mg oral capsule
Study NCT06748287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iGrow Hair Growth System
Description: has a helmet-design and headphones to allow for hands-free use and music listening capabilities. Treatment is 25 minutes every other day. three to four times per week for 4 months.
Study NCT00991718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 IV injection (labeled)
Description: 10 mcg (in 2 mL) IV dose of 14C-GDC-0449